Regulatory Drug Safety Alert · CDSCO · Ministry of Health & Family Welfare

India's War on Irrational FDCs

Over 600 fixed-dose combinations banned across four decades — the definitive timeline of how India systematically dismantled irrational drug combinations from its pharmacopoeia.

Updated Nov 2025 · Section 26A, Drugs & Cosmetics Act 1940 · CDSCO / DCGI
600+
FDCs Banned Total
156
Banned Aug 2024
328
Banned in 2018
1983
First Bans
💊
What is an FDC?
Fixed-Dose Combination — the basics

A Fixed-Dose Combination (FDC) is a pharmaceutical product containing two or more active ingredients in a fixed ratio, combined in a single dosage form. When the combination has a rational scientific basis — improved efficacy, reduced toxicity, or better compliance — FDCs are valuable clinical tools.

However, irrational FDCs — combinations that serve no pharmacological logic, mask adverse effects, increase toxicity risk, or simply reduce production costs — pose serious public health hazards. India's market was historically flooded with thousands of such combinations, many approved by state regulators without adequate clinical evidence.

Legal Basis

Section 26A of the Drugs & Cosmetics Act, 1940 empowers the Central Government to prohibit the manufacture, sale, or distribution of any drug "in the interest of the public." This provision was dormant for decades before being wielded systematically from 2016 onward following the Kokate Committee's landmark 2014 report.

📅
A Decade-by-Decade Timeline
From isolated bans to sweeping reform
1983 — The Foundation
First Systemic Bans Under Schedule J
India imposed early prohibitions on drugs with known toxicity risks. Amidopyrine (aminophenazone) was banned due to agranulocytosis risk. Phenacetin was withdrawn following evidence of nephrotoxic analgesic nephropathy and urothelial carcinoma. These early bans set the conceptual precedent for Section 26A action decades later.
2014 — The Kokate Committee
Expert Panel Flags 6,000+ Irrational Combinations
A government-appointed expert committee chaired by Prof. C.K. Kokate reviewed FDCs approved by state licensing authorities (SLAs) without Central approval. The committee identified thousands of combinations with no scientific rationale. Its report directly triggered the 2016 mega-ban.
2016 — The Mega-Ban
344 FDCs Prohibited in One Stroke
On 10 March 2016, the Ministry of Health & Family Welfare issued S.O. 733(E), banning 344 FDCs under Section 26A. This was challenged in the Delhi High Court, which stayed the order. The Supreme Court ultimately upheld the ban in December 2017, ruling the government had adequate grounds for prohibition. The legal fight by pharma companies including Pfizer, Abbott, and Macleods ultimately failed.
2018 — The Household Name Bans
328 More FDCs Banned — Saridon, Corex, Panderm Among Them
S.O. 4666(E) · Sep 2018 328 Combinations
The September 2018 gazette notified bans on 328 FDCs based on recommendations of the Drugs Technical Advisory Board (DTAB). Many were household brands:
Saridon (Paracetamol + Propyphenazone + Caffeine)
Corex Cough Syrup (Codeine + Chlorpheniramine)
Panderm (Neomycin + Clotrimazole + Beclomethasone + Lidocaine)
Glucon-D formulations (combination variants)
Piriton Expectorant (Chlorpheniramine + Ammonium Chloride)
Various Paracetamol + Nimesulide combos

The 2018 bans were particularly significant because many of these were over-the-counter bestsellers with decades of brand recognition. Their withdrawal demonstrated that commercial success provides no shield against a Section 26A prohibition when therapeutic rationale is absent.

2019 — Round Three
80 Additional FDCs Banned
A further 80 FDCs were prohibited after DTAB review. These largely comprised analgesic-antibiotic combinations and topical steroid multi-drug mixtures that had continued circulating despite earlier regulatory pressure. Many were combinations of NSAIDs with muscle relaxants or vitamins that lacked evidence-based dosage justification.
2023 — Continued Scrutiny
14 FDCs Prohibited
File No. 4-01/2021-DC
CDSCO continued its rolling review of FDCs approved by SLAs, banning 14 more combinations in 2023. These included certain antibiotic + enzyme combinations, antihistamine + decongestant combos, and multi-ingredient gastric preparations whose components had not been individually approved for their claimed indications.
Aug 2024 — Largest Single Action Since 2016
156 FDCs Banned — The August 2024 Gazette
S.O. 3285(E) – 3440(E) 156 Combinations Multiple Gazette Notifications
In August 2024, CDSCO issued a sweeping order prohibiting 156 FDCs across multiple gazette notifications (S.O. 3285(E) through 3440(E)). The categories targeted included:
Apr 2025 — Latest Action
35 FDCs Banned
File No. 4-01/2023-DC 35 Combinations
The most recent batch notification (April 2025) prohibited 35 FDCs under File No. 4-01/2023-DC. These included combinations identified through ongoing post-market surveillance and DTAB-DTAB sub-committee reviews, with particular attention to antimicrobial stewardship concerns — combinations that, by their irrational formulation, drove inappropriate antibiotic prescribing.
⚠️
Why Irrational FDCs Are Dangerous
The clinical and public health case for these bans

Irrational FDCs represent one of the most insidious forms of pharmaceutical harm — they look like medicine but undermine therapeutic goals. The harms operate through several mechanisms:

🔬 Therapeutic Harm

Fixed ratios prevent dose titration of individual components. A patient requiring a higher dose of one component must accept a disproportionately high dose of another, increasing adverse effect burden without therapeutic gain.

🦠 Antimicrobial Resistance

Irrational antibiotic combinations — particularly those pairing antibiotics with enzymes or vitamins — encourage inappropriate prescribing, prolong sub-therapeutic exposures, and directly accelerate resistance emergence.

💰 Economic Harm

FDCs are typically priced higher than equivalent single-drug formulations. Patients paying premium prices for irrational combinations are, in effect, subsidising pharmaceutical marketing rather than receiving clinical benefit.

🏥 Diagnostic Masking

Multi-component combinations — particularly topical steroid + antifungal + antibacterial creams — mask clinical signs, delay accurate diagnosis, and convert self-limiting conditions into chronic treatment-dependent states.

⚖️
Regulatory Framework
How the bans are executed

The procedural pathway for banning an FDC in India involves multiple checkpoints:

Key Regulators

CDSCO (Central Drugs Standard Control Organisation) — nodal agency under Ministry of Health & Family Welfare. DCGI (Drugs Controller General of India) — heads CDSCO and signs gazette notifications. DTAB (Drugs Technical Advisory Board) — statutory expert body providing recommendations. SLAs (State Licensing Authorities) — historically approved FDCs at state level, often without central scrutiny, creating the proliferation that necessitated these bans.

📋
Ban Summary at a Glance
Cumulative record of FDC prohibitions
Year Notification # FDCs Key Drugs / Notes
1983 Schedule J Amendments ~10 Amidopyrine, Phenacetin — foundational safety bans
2016 S.O. 733(E) · 10 Mar 344 Post-Kokate Committee; Supreme Court upheld Dec 2017
2018 S.O. 4666(E) · Sep 328 Saridon, Corex, Panderm — household names removed
2019 Multiple SOs 80 Analgesic-antibiotic combos, topical steroids
2023 File 4-01/2021-DC 14 Antibiotic-enzyme combos; SLA-approved products
Aug 2024 S.O. 3285(E)–3440(E) 156 Analgesics, vitamins, cough syrups, antibiotics
Apr 2025 File 4-01/2023-DC 35 AMR-focused; antimicrobial stewardship priority
CUMULATIVE TOTAL (as of Nov 2025) 600+ Ongoing rolling review by CDSCO
Section 26A Drugs & Cosmetics Act 1940 CDSCO / DCGI DTAB FDC Bans Irrational Drug Combinations Kokate Committee Antimicrobial Stewardship Drug Safety Pharmacovigilance
From standard textbooks & official gazette notifications  ·  Created by Myth Meets Molecules  ·  RGUHS Pharmacology Practicals